Login to Your Account



FILING IN DMD THIS YEAR, BUT . . .

'Exon' spill: Sarepta says FDA greased path for eteplirsen NDA, available data set OK

By Randy Osborne
Staff Writer

Monday, April 21, 2014
Breaking the silence that has prevailed since last November on the upshot of ongoing talks with the FDA regarding eteplirsen, Sarepta Therapeutics Inc. said the FDA's once-dim view of data with the exon-skipping candidate for Duchenne muscular dystrophy (DMD) has changed.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription